CoChat

Comprehensive, comparative evaluation of 25 automated SARS-CoV-2 serology assays

Open access
Dimech, Wayne, Curley, Shannon, Cai, Jing Jing · 2024 · Microbiology Spectrum

The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.

Abstract

The onset of the COVID-19 pandemic resulted in hundreds of in vitro devices coming to market, facilitated by regulatory authorities allowing “Emergency Use,” without a prior comprehensive evaluation of performance. The World Health Organization released Target Product Profiles specifying acceptable performance characteristics for SARS-CoV-2 devices. We evaluated 16 automated serology test kits that detect IgG or Total antibodies to SARS-CoV-2, along with a further nine tests that detect IgM-specific antibodies. All IgG or Total antibody tests reported a concordance with recent infection at 83.9% or greater, with 11/16 tests having greater than 90% sensitivity. All 16 tests reported greater than 96.3% specificity. There was a low level of false reactivity when testing all 25 tests on panels of samples containing potentially cross-reacting or interfering substances. A range of results were reported when testing seroconversion and dilution panels. The study further demonstrates that a comprehensive evaluation of the performance of test kits assessed against defined specifications is essential for the selection of test kits, especially in a pandemic setting. IMPORTANCE: We have previously highlighted the fact that hundreds of SARS-CoV-2 serology tests were released months after the onset of the COVID-19 pandemic. Of the hundreds of studies investigating the test kits’ performance, few were comparative reports, using the same comprehensive sample set across multiple tests. Recently, we reported a comparative assessment of 35 rapid diagnostic tests (RDTs) or microtiter plate enzyme immunoassays (EIA) for use in low- and middle-income countries, using a large sample set from individuals with a history of COVID-19. Only a few tests meet WHO Target Product Profile performance requirements. This study reports on the performance of a further 25 automated SARS-CoV-2 immunoassays using the same panel of samples. The results highlight the better analytical and clinical performance of automated serology test kits compared with RDTs, and the importance of independent comparative assessments to inform the use and procurement of these tests for both diagnostic and epidemiological investigations.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1128/spectrum.03228-23

Cites

21 of 21 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig 1 Concordances with recent infection (n = 199), and specificities (n = 300) of automated SARS-CoV-2 serology testing for either IgG or Total antibodies. Concordance and specificity results are presented as a heat map, with shades of green representing results of >90%, and shades of yellow representing results of between 60% and 90%.
Fig 1 Concordances with recent infection (n = 199), and specificities (n = 300) of automated SARS-CoV-2 serology testing for either IgG or Total antibodies. Concordance and specificity results are presented as a heat map, with shades of green representing results of >90%, and shades of yellow representing results of between 60% and 90%.CC BY · PubMed Central
Fig 2 Results of testing two lots (A and B) of automated SARS-CoV-2 IgG or Total antibody test kits on three serial dilutions of antibody-positive samples, with R indicating reactive results and NR indicating non-reactive results.
Fig 2 Results of testing two lots (A and B) of automated SARS-CoV-2 IgG or Total antibody test kits on three serial dilutions of antibody-positive samples, with R indicating reactive results and NR indicating non-reactive results.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 2

  1. Medical Device Coordination Group (MDCG). 2021. Guidance on performance evaluation of SARS-CoV-2 in vitro diagnostic medical devices. MDCG.
  2. World Health Organization. 2020. Advice on the use of point-of-care immunodiagnostic tests for COVID-19. WHO Headquarters (HQ), WHO, Geneva, Switzerland.

Cited by

See all 4

Metadata

Authors
Dimech, W., Curley, S., & Cai, J. J.
Affiliations
National Serology Reference Laboratory , Fitzroy, Victoria, Australia
Corresponding author
Dimech, Wayne
Venue
Microbiology Spectrum
Published
2024-01-11
Volume
12
Issue
1
Pages
e0322823-e0322823
ISSN
2165-0497 (ISSN-L)
OpenAlex
W4389136688
Cited by
4
References
21
Citations by year
2026: 1 · 2025: 1 · 2024: 2
FWCI
0.83
Type
journal article
Language
en
Open access
Licence
Locations
  • Microbiology Spectrum (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Topics
  • Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 detection and testing
  • Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
  • Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
Keywords
SARS-CoV-2, COVID-19 pandemic, automated immunoassay, IgG, IgM, test performance evaluation, sensitivity and specificity, cross-reactivity, emergency use authorization, rapid diagnostic tests, seroconversion
MeSH terms
COVID-19, SARS-CoV-2, COVID-19 Testing, Antibodies, Viral, Humans, Immunoglobulin G, Sensitivity and Specificity, Pandemics

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.